Is Cidara Therapeutics Stock a Good Investment?
Cidara Therapeutics Investment Advice | CDTX |
- Examine Cidara Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Cidara Therapeutics' leadership team and their track record. Good management can help Cidara Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Cidara Therapeutics' business and its evolving consumer preferences.
- Compare Cidara Therapeutics' performance and market position to its competitors. Analyze how Cidara Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Cidara Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Cidara Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Cidara Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Cidara Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Cidara Therapeutics Stock
Researching Cidara Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 70.0% of the company shares are held by institutions such as insurance companies. The book value of Cidara Therapeutics was currently reported as 16.41. The company recorded a loss per share of 24.4. Cidara Therapeutics had not issued any dividends in recent years. The entity had 1:20 split on the 24th of April 2024.
To determine if Cidara Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Cidara Therapeutics' research are outlined below:
| Cidara Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 63.91 M. Net Loss for the year was (22.93 M) with loss before overhead, payroll, taxes, and interest of (21.65 M). | |
| Cidara Therapeutics currently holds about 53.08 M in cash with (22.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.74. | |
| Cidara Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 70.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Insider Trading |
Cidara Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Cidara Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cidara Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Cidara Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Cidara Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-03-23 | 2022-12-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2024-03-27 | 2023-12-31 | -0.1 | -0.04 | 0.06 | 60 | ||
2023-11-02 | 2023-09-30 | -0.16 | -0.09 | 0.07 | 43 | ||
2023-05-11 | 2023-03-31 | -0.04 | 0.03 | 0.07 | 175 | ||
2022-03-07 | 2021-12-31 | -0.34 | -0.26 | 0.08 | 23 | ||
2019-08-08 | 2019-06-30 | -0.57 | -0.49 | 0.08 | 14 | ||
2022-08-09 | 2022-06-30 | -0.28 | -0.19 | 0.09 | 32 | ||
2017-03-15 | 2016-12-31 | -0.79 | -0.88 | -0.09 | 11 |
Cidara Therapeutics Target Price Consensus
Cidara target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Cidara Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 5 | Strong Buy |
Most Cidara analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Cidara stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Cidara Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCidara Therapeutics Target Price Projection
Cidara Therapeutics' current and average target prices are 23.85 and 31.50, respectively. The current price of Cidara Therapeutics is the price at which Cidara Therapeutics is currently trading. On the other hand, Cidara Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Cidara Therapeutics Market Quote on 27th of February 2025
Target Price
Analyst Consensus On Cidara Therapeutics Target Price
Cidara Therapeutics Analyst Ratings
Cidara Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Cidara Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Cidara Therapeutics' financials, market performance, and future outlook by experienced professionals. Cidara Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Cidara Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cidara Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cidara Therapeutics backward and forwards among themselves. Cidara Therapeutics' institutional investor refers to the entity that pools money to purchase Cidara Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2024-12-31 | 55.5 K | Longwood Capital Partners Llc | 2024-12-31 | 54.5 K | Ikarian Capital, Llc | 2024-12-31 | 53.9 K | Geode Capital Management, Llc | 2024-12-31 | 53.1 K | Schonfeld Strategic Advisors Llc | 2024-12-31 | 49.6 K | Stempoint Capital Lp | 2024-12-31 | 47.6 K | Ubs Group Ag | 2024-12-31 | 46.9 K | Susquehanna International Group, Llp | 2024-12-31 | 42.6 K | Millennium Management Llc | 2024-12-31 | 36 K | Bvf Inc | 2024-12-31 | 1.1 M | Ra Capital Management, Llc | 2024-12-31 | 1.1 M |
Cidara Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 242.22 M.Market Cap |
|
Cidara Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.32) | |
| Return On Capital Employed | 56.79 | 59.63 | |
| Return On Assets | (0.31) | (0.32) | |
| Return On Equity | 3.21 | 3.37 |
Determining Cidara Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Cidara Therapeutics is a good buy. For example, gross profit margin measures Cidara Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Cidara Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Cidara Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cidara Therapeutics. Check Cidara Therapeutics' Beneish M Score to see the likelihood of Cidara Therapeutics' management manipulating its earnings.
Evaluate Cidara Therapeutics' management efficiency
Cidara Therapeutics has return on total asset (ROA) of (0.2389) % which means that it has lost $0.2389 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0046) %, meaning that it created substantial loss on money invested by shareholders. Cidara Therapeutics' management efficiency ratios could be used to measure how well Cidara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cidara Therapeutics' Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to rise to 3.37 in 2025, whereas Return On Tangible Assets are likely to drop (0.32) in 2025. At this time, Cidara Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Other Current Assets is likely to rise to about 4.5 M in 2025, whereas Total Assets are likely to drop slightly above 71.9 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.16) | (2.05) | |
| Tangible Book Value Per Share | (2.16) | (2.05) | |
| Enterprise Value Over EBITDA | (1.42) | (1.49) | |
| Price Book Value Ratio | (7.61) | (7.99) | |
| Enterprise Value Multiple | (1.42) | (1.49) | |
| Price Fair Value | (7.61) | (7.99) | |
| Enterprise Value | 44.3 M | 54.5 M |
Understanding the operational decisions made by Cidara Therapeutics management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 0.938 |
Basic technical analysis of Cidara Stock
As of the 27th of February, Cidara Therapeutics shows the mean deviation of 4.21, and Risk Adjusted Performance of 0.0951. Cidara Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cidara Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cidara Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cidara Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cidara Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cidara Therapeutics' Outstanding Corporate Bonds
Cidara Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cidara Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cidara bonds can be classified according to their maturity, which is the date when Cidara Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US171779AL52 Corp BondUS171779AL52 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| CIMAREX ENERGY 39 Corp BondUS171798AD34 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Cidara Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Cidara Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0951 | |||
| Market Risk Adjusted Performance | 1.84 | |||
| Mean Deviation | 4.21 | |||
| Semi Deviation | 5.01 | |||
| Downside Deviation | 5.53 | |||
| Coefficient Of Variation | 852.71 | |||
| Standard Deviation | 5.96 | |||
| Variance | 35.56 | |||
| Information Ratio | 0.1167 | |||
| Jensen Alpha | 0.6918 | |||
| Total Risk Alpha | 0.7417 | |||
| Sortino Ratio | 0.1258 | |||
| Treynor Ratio | 1.83 | |||
| Maximum Drawdown | 32.32 | |||
| Value At Risk | (8.38) | |||
| Potential Upside | 12.65 | |||
| Downside Variance | 30.59 | |||
| Semi Variance | 25.09 | |||
| Expected Short fall | (4.39) | |||
| Skewness | 0.5934 | |||
| Kurtosis | 1.69 |
| Risk Adjusted Performance | 0.0951 | |||
| Market Risk Adjusted Performance | 1.84 | |||
| Mean Deviation | 4.21 | |||
| Semi Deviation | 5.01 | |||
| Downside Deviation | 5.53 | |||
| Coefficient Of Variation | 852.71 | |||
| Standard Deviation | 5.96 | |||
| Variance | 35.56 | |||
| Information Ratio | 0.1167 | |||
| Jensen Alpha | 0.6918 | |||
| Total Risk Alpha | 0.7417 | |||
| Sortino Ratio | 0.1258 | |||
| Treynor Ratio | 1.83 | |||
| Maximum Drawdown | 32.32 | |||
| Value At Risk | (8.38) | |||
| Potential Upside | 12.65 | |||
| Downside Variance | 30.59 | |||
| Semi Variance | 25.09 | |||
| Expected Short fall | (4.39) | |||
| Skewness | 0.5934 | |||
| Kurtosis | 1.69 |
Consider Cidara Therapeutics' intraday indicators
Cidara Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cidara Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cidara Therapeutics Corporate Filings
F3 | 26th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 18th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 2nd of January 2025 Other Reports | ViewVerify |
Cidara Stock media impact
Far too much social signal, news, headlines, and media speculation about Cidara Therapeutics that are available to investors today. That information is available publicly through Cidara media outlets and privately through word of mouth or via Cidara internal channels. However, regardless of the origin, that massive amount of Cidara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Cidara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Cidara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Cidara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Cidara Therapeutics alpha.
Cidara Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Cidara Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cidara Therapeutics Corporate Management
| Carol Waldo | VP Assurance | Profile | |
| James Balkovec | VP Research | Profile | |
| Taylor Sandison | Acting Chief Medical Officer | Profile | |
| SPHR CCP | Senior Culture | Profile | |
| Jim MBA | Chief Officer | Profile |
Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.